Infos zu Corona - Aktuelle Informationen zu SARS-CoV-2 : Impfungen Wuhan-type Originalvirus: in D in Vergangenheit verfügbare Impfstoffe gegen Originalvirus » Spikevax (Moderna)

Impfungen Wuhan-type Originalvirus: in D in Vergangenheit verfügbare Impfstoffe gegen Originalvirus » Spikevax (Moderna) - Original

Letzte Änderung: 25.10.2022 um 13:41 Uhr

Moderna wurde als zweiter Impfstoff gegen Corona in der EU/ Deutschland zugelassen. Stand Herbst 2022 sieht es so aus, als ob dieser Impfstoff von den derzeit verfügbaren Impfstoffen für die ersten zwei Impfdosen am besten wirken würde. Bei den ersten beiden Impfungen werden jeweils 100 mcg geimpft, als Booster nurnoch 50 mcg.

Bei jungen (insbes. männlichen) Erwachsenen besteht ein erhöhtes Risiko von Herzmuskelentzündungen, weshalb teils empfohlen wird es nur an Personen über 30 Jahre zu verimpfen.

Weiterführende Links zum Artikel

★ Bivalent COVID Booster Ph 2/3 Interim Analysis (mRNA-1273.214) (Hinzugefügt: 13.06.2022 um 09:32 Uhr)
https://s29.q4cdn.com/435878511/files/doc_presentations/2022/06/08/Master-Final-Bivalent-Omicron-Data-Update-0608.pdf
★ MODERNA ANNOUNCES ITS COVID-19 VACCINE PHASE 2/3 STUDY IN CHILDREN 6 MONTHS TO UNDER 6 YEARS HAS SUCCESSFULLY MET ITS PRIMARY ENDPOINT (Hinzugefügt: 27.03.2022 um 08:13 Uhr)
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-its-COVID-19-Vaccine-Phase-23-Study-in-Children-6-Months-to-Under-6-Years-Has-Successfully-Met-Its-Primary-Endpoint/default.aspx
★ Booster mit mRNA-1273 führt nach 4 Wochen zu deutlichem Anstieg von neutralisierenden Antikörpern gegen Omikron (Hinzugefügt: 20.12.2021 um 16:36 Uhr)
https://www.aerzteblatt.de/nachrichten/130253/Booster-mit-mRNA-1273-fuehrt-nach-4-Wochen-zu-deutlichem-Anstieg-von-neutralisierenden-Antikoerpern-gegen-Omikron
★ MODERNA ANNOUNCES PRELIMINARY BOOSTER DATA AND UPDATES STRATEGY TO ADDRESS OMICRON VARIANT (Hinzugefügt: 20.12.2021 um 11:51 Uhr)
https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Preliminary-Booster-Data-and-Updates-Strategy-to-Address-Omicron-Variant/default.aspx
★ Spikevax (previously COVID-19 Vaccine Moderna) (Hinzugefügt: 18.10.2021 um 09:59 Uhr)
https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax
★ Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase (Hinzugefügt: 23.09.2021 um 10:04 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2113017
★ Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 (Hinzugefügt: 19.09.2021 um 14:41 Uhr)
https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm
★ Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report (Hinzugefügt: 18.02.2021 um 08:01 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2102179
★ Product Information as approved by the CHMP on 6 January 2021, pending endorsement by the European Commission (Hinzugefügt: 10.01.2021 um 09:32 Uhr)
https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-product-information_en.pdf
★ EMA: COVID-19 Vaccine Moderna (Hinzugefügt: 10.01.2021 um 09:31 Uhr)
https://www.ema.europa.eu/en/medicines/human/summaries-opinion/covid-19-vaccine-moderna
★ Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (Hinzugefügt: 31.12.2020 um 11:15 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2035389
MODERNA ANNOUNCES OMICRON-CONTAINING BIVALENT BOOSTER CANDIDATE MRNA-1273.214 DEMONSTRATES SUPERIOR ANTIBODY RESPONSE AGAINST OMICRON (Hinzugefügt: 24.06.2022 um 09:35 Uhr)
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx
Covid-19-Impfstoff von Moderna in der Schweiz für Kinder zwischen 6 und 11 Jahren zugelassen (Hinzugefügt: 15.05.2022 um 10:28 Uhr)
https://www.swissmedic.ch/swissmedic/de/home/news/coronavirus-covid-19/covid-19-impfstoff-moderna-fuer-kinder-6-11-jahren-zugelassen.html
MODERNA FILES FOR AUTHORIZATION OF ITS COVID-19 VACCINE IN YOUNG CHILDREN SIX MONTHS TO UNDER SIX YEARS OF AGE (Hinzugefügt: 30.04.2022 um 11:47 Uhr)
https://investors.modernatx.com/news/news-details/2022/Moderna-Files-for-Authorization-of-Its-COVID-19-Vaccine-in-Young-Children-Six-Months-to-Under-Six-Years-of-Age/default.aspx
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours (Hinzugefügt: 27.04.2022 um 15:56 Uhr)
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00203-0/fulltext
Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine (Hinzugefügt: 26.04.2022 um 13:35 Uhr)
https://www.researchsquare.com/article/rs-1555201/v1
MODERNA ANNOUNCES CLINICAL UPDATE ON BIVALENT COVID-19 BOOSTER PLATFORM (Hinzugefügt: 26.04.2022 um 13:27 Uhr)
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Clinical-Update-on-Bivalent-COVID-19-Booster-Platform/default.aspx
COVID-19: Bivalenter Impfstoff von Moderna erzielt stärkere Boosterwirkung (Hinzugefügt: 26.04.2022 um 13:23 Uhr)
https://www.aerzteblatt.de/nachrichten/133495/COVID-19-Bivalenter-Impfstoff-von-Moderna-erzielt-staerkere-Boosterwirkung
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing antibodies and protection against Omicron (Hinzugefügt: 27.03.2022 um 07:52 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(22)00388-9
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial (Hinzugefügt: 11.03.2022 um 11:22 Uhr)
https://www.nature.com/articles/s41591-022-01739-w.epdf?sharing_token=eGurssEUn_J4gcNMTEP13NRgN0jAjWel9jnR3ZoTv0N1YipEX1TbaAre7g75CzBxMWX5rW_M1jAgmvopjV_QX-AlLVxwpz05ZRrVY4JowB87rmOy__6efAr94Vlg7JLAzx_tobVfSQPYRiTYMhR24t2x_WXT72-1Aij2gZle17Y%3D
EMA recommends approval of Spikevax for children aged 6 to 11 Share (Hinzugefügt: 06.03.2022 um 18:59 Uhr)
https://www.ema.europa.eu/en/news/ema-recommends-approval-spikevax-children-aged-6-11
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination (Hinzugefügt: 17.02.2022 um 06:50 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2119912
Moderna starts clinical trial of booster shot targeting omicron Covid variant (Hinzugefügt: 17.02.2022 um 05:56 Uhr)
https://www.cnbc.com/2022/01/26/moderna-starts-clinical-trial-of-booster-shot-targeting-omicron-covid-variant.html
Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice (Hinzugefügt: 14.02.2022 um 16:10 Uhr)
https://www.biorxiv.org/content/10.1101/2022.02.07.479419v1
mRNA-1273 vaccine-induced antibodies maintain Fc-effector functions across SARS-CoV-2 Variants of Concern (Hinzugefügt: 10.01.2022 um 11:27 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(22)00030-9
STIKO prüft Moderna für unter 30-Jährige (Hinzugefügt: 23.12.2021 um 19:48 Uhr)
https://www.aerzteblatt.de/nachrichten/130350/STIKO-prueft-Moderna-fuer-unter-30-Jaehrige
COVID-19: Myokarditis in Dänemark nach Moderna-Impfstoff häufiger (Hinzugefügt: 18.12.2021 um 14:34 Uhr)
https://www.aerzteblatt.de/nachrichten/130201/COVID-19-Myokarditis-in-Daenemark-nach-Moderna-Impfstoff-haeufiger
Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies (Hinzugefügt: 17.12.2021 um 13:14 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.15.21267805v1
Booster kann schwächere neutralisierende Wirkung von mRNA-1273 gegen Omikron teilweise ausgleichen (Hinzugefügt: 17.12.2021 um 09:50 Uhr)
https://www.aerzteblatt.de/nachrichten/130160/Booster-kann-schwaechere-neutralisierende-Wirkung-von-mRNA-1273-gegen-Omikron-teilweise-ausgleichen
Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques is coincident with anamnestic antibody response in the lung (Hinzugefügt: 04.12.2021 um 09:15 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)01405-7
Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study (Hinzugefügt: 01.12.2021 um 18:10 Uhr)
https://www.sciencedirect.com/science/article/pii/S2667193X21001307
Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant (Hinzugefügt: 28.11.2021 um 15:14 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-strategy-address-omicron-b11529-sars-cov-2
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial (Hinzugefügt: 25.11.2021 um 18:46 Uhr)
https://www.science.org/doi/10.1126/science.abm3425
Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older (Hinzugefügt: 20.11.2021 um 11:06 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-fda-authorization-booster-dose-covid-19/
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial (Hinzugefügt: 19.11.2021 um 16:01 Uhr)
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00574-X/fulltext
Frankreich: Behörde rät von Moderna-Impfstoff für unter 30-Jährige ab (Hinzugefügt: 19.11.2021 um 15:58 Uhr)
https://www.aerzteblatt.de/nachrichten/128910/Frankreich-Behoerde-raet-von-Moderna-Impfstoff-fuer-unter-30-Jaehrige-ab
MYOKARDITIS: ANWENDUNGSBESCHRÄNKUNGEN FÜR mRNA-IMPFSTOFF VON MODERNA IN NORDISCHEN LÄNDERN (Hinzugefügt: 04.11.2021 um 19:04 Uhr)
https://www.arznei-telegramm.de/html/2021_10/2110079_02.html
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge (Hinzugefügt: 04.11.2021 um 08:41 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2115597
EU-Behörde empfiehlt Boosterimpfung mit Moderna-Vakzin (Hinzugefügt: 26.10.2021 um 18:43 Uhr)
https://www.aerzteblatt.de/nachrichten/128481/EU-Behoerde-empfiehlt-Boosterimpfung-mit-Moderna-Vakzin
EU-Behörde empfiehlt Boosterimpfung mit Moderna-Vakzin (Hinzugefügt: 26.10.2021 um 18:43 Uhr)
https://www.aerzteblatt.de/nachrichten/128481/EU-Behoerde-empfiehlt-Boosterimpfung-mit-Moderna-Vakzin
Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway (Hinzugefügt: 26.10.2021 um 09:07 Uhr)
https://www.biorxiv.org/content/10.1101/2021.10.23.465542v1
Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine–boosted nonhuman primates (Hinzugefügt: 25.10.2021 um 07:26 Uhr)
https://www.science.org/doi/10.1126/science.abl8912
Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison (Hinzugefügt: 21.10.2021 um 11:06 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2114089
mRNA-1273 BOOSTER DOSE (Hinzugefügt: 18.10.2021 um 10:39 Uhr)
https://www.fda.gov/media/152953/download
Fact Check: Have Finland, Sweden, Norway and Iceland 'Banned' Moderna Vaccine? (Hinzugefügt: 18.10.2021 um 09:51 Uhr)
https://www.newsweek.com/fact-check-has-sweden-denmark-norway-iceland-banned-moderna-vaccine-1638563
FDA-Gremium empfiehlt Auffrischungsimpfungen mit Moderna (Hinzugefügt: 16.10.2021 um 11:57 Uhr)
https://www.aerzteblatt.de/nachrichten/128200/FDA-Gremium-empfiehlt-Auffrischungsimpfungen-mit-Moderna
Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines (Hinzugefügt: 16.10.2021 um 11:54 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2115596
Moderna will mRNA-Impfstoffe in Afrika herstellen (Hinzugefügt: 12.10.2021 um 11:09 Uhr)
https://www.aerzteblatt.de/nachrichten/127946/Moderna-will-mRNA-Impfstoffe-in-Afrika-herstellen
Schweden und Dänemark setzen Moderna-Impfung für junge Menschen vorerst aus (Hinzugefügt: 07.10.2021 um 06:56 Uhr)
https://www.spiegel.de/wissenschaft/medizin/corona-schweden-setzt-moderna-impfung-fuer-junge-menschen-vorerst-aus-a-d5105c58-28f3-4018-956a-ceb6d5e4c524
Moderna COVID-19 vaccine generates long-lasting immune memory (Hinzugefügt: 06.10.2021 um 06:29 Uhr)
https://www.nih.gov/news-events/nih-research-matters/moderna-covid-19-vaccine-generates-long-lasting-immune-memory
Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants (Hinzugefügt: 04.10.2021 um 09:17 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v1
Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) (Hinzugefügt: 03.10.2021 um 07:57 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.29.21264089v1
Initial Analysis of Viral Dynamics and Circulating Viral Variants During the mRNA-1273 Phase 3 COVE Trial (Hinzugefügt: 02.10.2021 um 18:34 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.28.21264252v1
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase (Hinzugefügt: 24.09.2021 um 11:09 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2113017
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge (Hinzugefügt: 23.09.2021 um 10:05 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.17.21263624v1
SARS-CoV-2: Schutzwirkung von BNT162b2 lässt etwas schneller nach als bei mRNA-1273 (Hinzugefügt: 22.09.2021 um 10:31 Uhr)
https://www.aerzteblatt.de/nachrichten/127433/SARS-CoV-2-Schutzwirkung-von-BNT162b2-laesst-etwas-schneller-nach-als-bei-mRNA-1273
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates (Hinzugefügt: 20.09.2021 um 09:28 Uhr)
https://www.science.org/doi/10.1126/science.abj0299
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells (Hinzugefügt: 15.09.2021 um 16:08 Uhr)
https://www.science.org/doi/10.1126/science.abj9853
Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study (Hinzugefügt: 15.09.2021 um 15:56 Uhr)
https://www.bmj.com/content/374/bmj.n1943
Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine (Hinzugefügt: 15.09.2021 um 15:37 Uhr)
https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 (Hinzugefügt: 15.09.2021 um 15:03 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2783797
Moderna-Ampullen in Japan mit Edelstahlpartikeln verunreinigt (Hinzugefügt: 15.09.2021 um 14:57 Uhr)
https://www.aerzteblatt.de/nachrichten/126912/Moderna-Ampullen-in-Japan-mit-Edelstahlpartikeln-verunreinigt
COVID-19: Moderna beantragt allgemeine Zulassung für die dritte Dosis (Hinzugefügt: 15.09.2021 um 14:37 Uhr)
https://www.aerzteblatt.de/nachrichten/127018/COVID-19-Moderna-beantragt-allgemeine-Zulassung-fuer-die-dritte-Dosis
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (Hinzugefügt: 14.09.2021 um 07:27 Uhr)
https://www.science.org/doi/10.1126/science.abj4176
Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine (Hinzugefügt: 26.08.2021 um 04:00 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-completes-submission-biologics-license-application-us/
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial (Hinzugefügt: 24.08.2021 um 17:08 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.09.21261290v4
Deutschland verzichtet auf Millionen Impfdosen von Moderna (Hinzugefügt: 24.08.2021 um 16:59 Uhr)
https://www.br.de/nachrichten/deutschland-welt/deutschland-verzichtet-auf-millionen-corona-impfdosen-von-moderna,SfnLz7o?fbclid=IwAR2RpFiJqxWLrQOJMzia0AfFOgJtg6IVqFHcZJ51Ra5ZLNmvIoZGdz9VqNk
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents (Hinzugefügt: 24.08.2021 um 16:51 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2109522
Moderna gives bigger antibody boost than Pfizer in elderly: U of T researchers (Hinzugefügt: 24.08.2021 um 16:34 Uhr)
https://www.utoronto.ca/news/moderna-gives-bigger-antibody-boost-pfizer-elderly-u-t-researchers
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants (Hinzugefügt: 14.08.2021 um 08:57 Uhr)
https://science.sciencemag.org/content/early/2021/08/11/science.abj4176.full
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates (Hinzugefügt: 06.08.2021 um 10:45 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-reports-second-quarter-fiscal-year-2021-financial/
First results LUMC study skin vaccination with corona vaccine are promising (Hinzugefügt: 04.08.2021 um 08:57 Uhr)
https://www.lumc.nl/over-het-lumc/nieuws/2021/juni/onderzoek-huidprik-veelbelovend/?year=2021&month=5
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates (Hinzugefügt: 03.08.2021 um 10:17 Uhr)
https://science.sciencemag.org/content/early/2021/07/29/science.abj0299.full
Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis (Hinzugefügt: 13.07.2021 um 07:13 Uhr)
https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar (Hinzugefügt: 13.07.2021 um 07:12 Uhr)
https://www.nature.com/articles/s41591-021-01446-y
Quarter-dose of Moderna COVID vaccine still rouses a big immune response (Hinzugefügt: 09.07.2021 um 19:09 Uhr)
https://www.nature.com/articles/d41586-021-01893-0
Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory (Hinzugefügt: 07.07.2021 um 07:17 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.30.21259787v1
Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India (Hinzugefügt: 05.07.2021 um 18:47 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-clinical-update-neutralizing-activity-its-covid/
Incidence of SARS-CoV-2 Infection in Health Care Workers After a Single Dose of mRNA-1273 Vaccine (Hinzugefügt: 20.06.2021 um 17:44 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781173
Moderna beantragt EU-Zulassung für Impfung von Jugendlichen (Hinzugefügt: 09.06.2021 um 19:42 Uhr)
https://www.t-online.de/gesundheit/krankheiten-symptome/id_90174104/corona-impfung-moderna-beantragt-eu-zulassung-fuer-jugendliche.html
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection (Hinzugefügt: 09.06.2021 um 19:18 Uhr)
https://stm.sciencemag.org/content/early/2021/06/08/scitranslmed.abi9915.1.full
Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster (Hinzugefügt: 07.06.2021 um 08:01 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.05.21256716v1
Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine (Hinzugefügt: 06.06.2021 um 14:58 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-initiation-rolling-submission-biologics
Vaccine shopping to avoid Moderna shot is 'alarming,' unnecessary and potentially harmful, doctors say (Hinzugefügt: 25.05.2021 um 14:08 Uhr)
https://www.cbc.ca/news/canada/toronto/moderna-vaccine-preference-1.6034764
Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates (Hinzugefügt: 25.05.2021 um 13:56 Uhr)
https://www.biorxiv.org/content/10.1101/2021.05.21.445189v1
Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients (Hinzugefügt: 22.05.2021 um 17:49 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075
Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination (Hinzugefügt: 08.05.2021 um 12:13 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.06.21256403v1
Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates (Hinzugefügt: 07.05.2021 um 06:34 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-reports-first-quarter-fiscal-year-2021-financial-results
Modeling and Predicting Antibody Durability for mRNA-1273 Vaccine for SARS-CoV-2 Variants (Hinzugefügt: 06.05.2021 um 09:25 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.04.21256537v1
Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern (Hinzugefügt: 06.05.2021 um 09:09 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-initial-booster-data-against-sars-cov/
Resilient Fc-Effector Functions Across SARS-CoV-2 Variants of Concern Following mRNA-1273 Vaccination (Hinzugefügt: 29.04.2021 um 07:11 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3832979
Will Moderna COVID vaccine need a third dose? Here’s what we know so far (Hinzugefügt: 24.04.2021 um 05:55 Uhr)
https://www.miamiherald.com/news/coronavirus/article250890694.html
Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates (Hinzugefügt: 22.04.2021 um 12:30 Uhr)
https://www.biorxiv.org/content/10.1101/2021.04.20.440647v1
Moderna COVID vaccine could receive emergency authorization for children ages 12 to 15 within ‘weeks’ (Hinzugefügt: 20.04.2021 um 06:02 Uhr)
https://www.masslive.com/coronavirus/2021/04/moderna-covid-vaccine-could-receive-emergency-authorization-for-children-ages-12-to-15-within-weeks.html
https://www.nejm.org/doi/full/10.1056/NEJMc2103916 (Hinzugefügt: 17.04.2021 um 09:55 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2103916
The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD (Hinzugefügt: 15.04.2021 um 06:14 Uhr)
https://www.biorxiv.org/content/10.1101/2021.04.14.439844v1
Studie zu Corona-Vakzin Wirksamkeit von Moderna herabgestuft (Hinzugefügt: 14.04.2021 um 08:08 Uhr)
https://amp.zdf.de/nachrichten/panorama/corona-impfstoff-moderna-wirksamkeit-100.html?utm_source=upday&utm_medium=referral
Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day (Hinzugefügt: 14.04.2021 um 07:02 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-clinical-and-supply-updates-covid-19-vaccine/
Letter from the JCVI on use of the Moderna vaccine in the COVID-19 immunisation programme: 7 April 2021 (Hinzugefügt: 12.04.2021 um 18:07 Uhr)
https://www.gov.uk/government/publications/letter-from-the-health-and-social-care-secretary-on-use-of-the-moderna-vaccine/letter-from-the-jcvi-on-use-of-the-moderna-vaccine-in-the-covid-19-immunisation-programme-7-april-2021
People who got the Moderna COVID-19 vaccine say they have more side effects (Hinzugefügt: 09.04.2021 um 06:14 Uhr)
https://www.theverge.com/2021/4/7/22371665/covid-vaccine-side-effects-moderna-pfizer
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 (Hinzugefügt: 08.04.2021 um 06:22 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2103740
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 (Hinzugefügt: 07.04.2021 um 07:07 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2103916
Moderna Provides Storage Update & Announces the U.S. FDA Authorizes Up To 15-Doses Per Vial of its COVID-19 Vaccine (Hinzugefügt: 02.04.2021 um 20:03 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-storage-update-announces-us-fda-authorizes-15/
50 Prozent mehr pro Ampulle US-Behörde erweitert Moderna-Zulassung (Hinzugefügt: 02.04.2021 um 20:00 Uhr)
https://www.n-tv.de/panorama/US-Behoerde-erweitert-Moderna-Zulassung-article22467976.html
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (Hinzugefügt: 30.03.2021 um 08:25 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2028436
Diesen Brief schrieb Lonza an Bundesrat Alain Berset (Hinzugefügt: 29.03.2021 um 06:37 Uhr)
https://www.20min.ch/story/diesen-brief-schrieb-lonza-an-bundesrat-alain-berset-392552952538
Infection and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant (Hinzugefügt: 21.03.2021 um 07:11 Uhr)
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(21)00137-2
CORRESPONDENCE Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine (Hinzugefügt: 18.03.2021 um 05:45 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2102179
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population (Hinzugefügt: 17.03.2021 um 02:17 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-0/
Lonza gets licence to make ingredients for Moderna vaccine (Hinzugefügt: 16.03.2021 um 08:02 Uhr)
https://www.reuters.com/article/us-health-coronavirus-lonza-moderna-idUSKBN2B72BB
First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine (Hinzugefügt: 15.03.2021 um 15:05 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/first-participants-dosed-phase-1-study-evaluating-mrna-1283/
Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates (Hinzugefügt: 11.03.2021 um 08:38 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-study-evaluating/
Bern: Merkblatt: Aufziehen und Verimpfen von Impfstoffen ohne Totvolumenverlust (Hinzugefügt: 10.03.2021 um 08:13 Uhr)
https://www.gef.be.ch/gef/de/index/Corona/Corona/corona_impfung_bern/corona_impfung_informationen_fuer_fachpersonen.assetref/dam/documents/GEF/GS/de/impfen/Fachpersonen/Merkblatt_%20Aufziehen%20und%20Verimpfen%20von%20Impfstoffen%20ohne%20Totvolumenverlust
SARS-CoV-2: Allergische Spätreaktion auf mRNA-Vakzine von Moderna (Hinzugefügt: 05.03.2021 um 06:52 Uhr)
https://www.aerzteblatt.de/nachrichten/121767/SARS-CoV-2-Allergische-Spaetreaktion-auf-mRNA-Vakzine-von-Moderna
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (Hinzugefügt: 05.03.2021 um 06:44 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2102131
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (Hinzugefügt: 04.03.2021 um 08:06 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2102131
Moderna to begin trial of new COVID vaccine to address virus variant first found in South Africa (Hinzugefügt: 25.02.2021 um 19:59 Uhr)
https://eu.usatoday.com/story/news/health/2021/02/24/moderna-begin-trial-new-covid-vaccine-address-virus-variant/6802803002/
Moderna Announces Additional Capital Investments to Increase Global Manufacturing Capacity for COVID-19 Vaccine (Hinzugefügt: 25.02.2021 um 19:51 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-additional-capital-investments-increase-global/
Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study (Hinzugefügt: 25.02.2021 um 19:51 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-it-has-shipped-variant-specific-vaccine/
Moderna Provides U.S. COVID-19 Vaccine Supply Update (Hinzugefügt: 17.02.2021 um 03:25 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-us-covid-19-vaccine-supply-update-0/
Moderna will mehr Impfstoff pro Ampulle abfüllen (Hinzugefügt: 16.02.2021 um 11:39 Uhr)
https://www.aerzteblatt.de/nachrichten/121154/Moderna-will-mehr-Impfstoff-pro-Ampulle-abfuellen
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine (Hinzugefügt: 15.02.2021 um 08:48 Uhr)
https://www.sciencedirect.com/science/article/pii/S0264410X21001535
Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines (Hinzugefügt: 04.02.2021 um 09:40 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2776229
Luck, foresight and science: How an unheralded team developed a COVID-19 vaccine in record time (Hinzugefügt: 31.01.2021 um 10:08 Uhr)
https://eu.usatoday.com/in-depth/news/investigations/2021/01/26/moderna-covid-vaccine-science-fast/6555783002/
Moderna Provides U.S. COVID-19 Vaccine Supply Update (Hinzugefügt: 27.01.2021 um 09:36 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-us-covid-19-vaccine-supply-update/
Vaccine 2.0: Moderna and other companies plan tweaks that would protect against new coronavirus mutations (Hinzugefügt: 27.01.2021 um 09:30 Uhr)
https://www.sciencemag.org/news/2021/01/vaccine-20-moderna-and-other-companies-plan-tweaks-would-protect-against-new
Dr. Anthony Fauci Applauds Moderna's Program to Create COVID-19 Booster for South African Variant (Hinzugefügt: 26.01.2021 um 12:53 Uhr)
https://www.newsweek.com/dr-anthony-fauci-applauds-modernas-program-create-covid-19-booster-south-african-variant-1564215
Moderna coronavirus vaccine doses can be spaced up to six weeks but pregnant women should avoid jab, says WHO (Hinzugefügt: 26.01.2021 um 12:53 Uhr)
https://www.independent.co.uk/news/health/moderna-vaccine-covid-spacing-pregnant-b1792784.html
SARS-CoV-2: Schutzwirkung von Moderna-Impfstoff gegen südafrikanische Variante könnte schnell nachlassen (Hinzugefügt: 26.01.2021 um 08:41 Uhr)
https://www.aerzteblatt.de/nachrichten/120497/SARS-CoV-2-Schutzwirkung-von-Moderna-Impfstoff-gegen-suedafrikanische-Variante-koennte-schnell-nachlassen
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants (Hinzugefügt: 26.01.2021 um 08:38 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1
Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa (Hinzugefügt: 26.01.2021 um 08:38 Uhr)
https://investors.modernatx.com/node/10841/pdf
Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa (Hinzugefügt: 26.01.2021 um 08:35 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-covid-19-vaccine-retains-neutralizing-activity-against/
COVID-19-IMPFSTOFF VON MODERNA (Hinzugefügt: 22.01.2021 um 19:15 Uhr)
https://www.arznei-telegramm.de/html/2021_01/2101001_02.html
SARS-CoV-2: Laborexperimente deuten auf verminderte Schutzwirkung gegen neue Varianten hin (Hinzugefügt: 22.01.2021 um 09:10 Uhr)
https://www.aerzteblatt.de/nachrichten/120379/SARS-CoV-2-Laborexperimente-deuten-auf-verminderte-Schutzwirkung-gegen-neue-Varianten-hin
SCHWERE ALLERGISCHE IMPFREAKTIONEN Moderna: Über 300.000 Impfungen sollen zurückgehalten werden (Hinzugefügt: 19.01.2021 um 12:41 Uhr)
https://m.apotheke-adhoc.de/nachrichten/detail/internationales/moderna-ueber-300000-impfungen-sollen-zurueckgehalten-werden-schwere-allergische-impfreaktionen/
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (Hinzugefügt: 19.01.2021 um 07:14 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2032195
California State Epidemiologist Statement Recommending Providers Pause Administration of Single Lot of Moderna COVID-19 Vaccine (Hinzugefügt: 18.01.2021 um 21:07 Uhr)
https://www.cdph.ca.gov/Programs/OPA/Pages/NR21-021.aspx
Moderna believes it could update its coronavirus vaccine without a big new trial (Hinzugefügt: 15.01.2021 um 06:52 Uhr)
https://www.technologyreview.com/2021/01/13/1016098/moderna-variant-coronavirus-vaccine-update/
Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland (Hinzugefügt: 13.01.2021 um 08:23 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/swissmedic-authorizes-covid-19-vaccine-moderna-use-switzerland/
Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States (Hinzugefügt: 11.01.2021 um 08:20 Uhr)
https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
Ausschuss für Humanarzneimittel CHMP empfiehlt bedingte Zulassung für den COVID-19-Impfstoff von Moderna (Hinzugefügt: 10.01.2021 um 09:33 Uhr)
https://www.pei.de/DE/newsroom/hp-meldungen/2021/210106-ema-empfiehlt-bedingte-zulassung-covid-19-impfstoff-moderna.html;jsessionid=452AFDF4FA79320EA01A4E9CD0947A94.intranet221?nn=221090
Paul- Ehrlich- Institut: Europäische Kommission erteilt Zulassung für den COVID-19-Impfstoff von Moderna für die Europäische Union (Hinzugefügt: 10.01.2021 um 09:32 Uhr)
https://www.pei.de/DE/newsroom/hp-meldungen/2021/210106-eu-zulassung-covid-19-impfstoff-moderna.html;jsessionid=452AFDF4FA79320EA01A4E9CD0947A94.intranet221?nn=221090
Japanese approval of Moderna COVID-19 vaccine unlikely before May (Hinzugefügt: 09.01.2021 um 10:24 Uhr)
https://www.japantimes.co.jp/news/2021/01/07/national/science-health/japan-moderna-vaccine/
Moderna vaccine becomes third COVID-19 vaccine approved by UK regulator (Hinzugefügt: 08.01.2021 um 18:29 Uhr)
https://www.gov.uk/government/news/moderna-vaccine-becomes-third-covid-19-vaccine-approved-by-uk-regulator
Maintaining Safety with SARS-CoV-2 Vaccines (Hinzugefügt: 08.01.2021 um 10:17 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMra2035343
Moderna CEO says vaccine likely to protect for 'couple of years' (Hinzugefügt: 08.01.2021 um 09:41 Uhr)
https://www.reuters.com/article/us-health-coronavirus-moderna-vaccine/moderna-ceo-says-vaccine-likely-to-protect-for-couple-of-years-idUSKBN29C0YK
U.S. officials report more severe allergic reactions to COVID-19 vaccines (Hinzugefügt: 07.01.2021 um 05:15 Uhr)
https://www.reuters.com/article/us-health-coronavirus-vaccines-allergy-idUSKBN29B2GS
Peter Doshi: Pfizer and Moderna’s “95% effective” vaccines—we need more details and the raw data (Hinzugefügt: 07.01.2021 um 04:55 Uhr)
https://blogs.bmj.com/bmj/2021/01/04/peter-doshi-pfizer-and-modernas-95-effective-vaccines-we-need-more-details-and-the-raw-data/
EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU (Hinzugefügt: 07.01.2021 um 04:53 Uhr)
https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu
Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel (Hinzugefügt: 05.01.2021 um 16:57 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/israeli-ministry-health-authorizes-covid-19-vaccine-moderna-use/
FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines (Hinzugefügt: 05.01.2021 um 08:18 Uhr)
https://www.fda.gov/news-events/press-announcements/fda-statement-following-authorized-dosing-schedules-covid-19-vaccines
Moderna Provides COVID-19 Vaccine Supply Update (Hinzugefügt: 05.01.2021 um 08:01 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-covid-19-vaccine-supply-update/
Peer-reviewed report on Moderna COVID-19 vaccine publishes (Hinzugefügt: 01.01.2021 um 19:17 Uhr)
https://www.nih.gov/news-events/news-releases/peer-reviewed-report-moderna-covid-19-vaccine-publishes
Kanada erlaubt Einsatz von Modernas Coronaimpfstoff (Hinzugefügt: 28.12.2020 um 19:12 Uhr)
https://www.aerzteblatt.de/nachrichten/119732/Kanada-erlaubt-Einsatz-von-Modernas-Coronaimpfstoff
Celebrities beware! Moderna vaccine can cause swelling in people with facial fillers, dermatologist warns (Hinzugefügt: 26.12.2020 um 10:04 Uhr)
https://www.dailymail.co.uk/news/article-9087415/Moderna-vaccine-causes-swelling-lip-fillers-warned.html
Boston Doctor Reports Serious Allergic Reaction After Getting Moderna’s Covid Vaccine (Hinzugefügt: 26.12.2020 um 10:04 Uhr)
https://www.nytimes.com/2020/12/25/health/Covid-moderna-vaccine-allergies.html?action=click&module=Top%20Stories&pgtype=Homepage
Regulatory Decision Summary - Moderna COVID-19 Vaccine - Health Canada (Hinzugefügt: 23.12.2020 um 20:28 Uhr)
https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00736
Dr Fauci gives thumbs up as he receives Covid vaccine (Hinzugefügt: 23.12.2020 um 08:41 Uhr)
https://www.independent.co.uk/news/world/americas/anthony-fauci-covid-vaccine-moderna-b1777697.html
Der Impfstoff mRNA-1273 (Moderna) zur Impfung gegen Corona (Hinzugefügt: 23.12.2020 um 08:31 Uhr)
https://www.gesundheitsinformation.de/der-impfstoff-mrna-1273-moderna-zur-impfung-gegen.3544.de.html?part=corm-co
Canada: Statement on the U.S. authorization of the Moderna COVID-19 vaccine (Hinzugefügt: 21.12.2020 um 10:53 Uhr)
https://www.canada.ca/en/health-canada/news/2020/12/statement-on-the-us-authorization-of-the-moderna-covid-19-vaccine.html
EU-Kommission zieht Option auf weitere 80 Millionen Impfstoffdosen von Moderna (Hinzugefügt: 20.12.2020 um 09:30 Uhr)
https://www.aerzteblatt.de/nachrichten/119591/EU-Kommission-zieht-Option-auf-weitere-80-Millionen-Impfstoffdosen-von-Moderna
FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine (Hinzugefügt: 19.12.2020 um 09:27 Uhr)
https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid
Update on assessment of marketing authorisation application for Moderna’s mRNA-1273 COVID-19 vaccine (Hinzugefügt: 18.12.2020 um 10:32 Uhr)
https://www.ema.europa.eu/en/news/update-assessment-marketing-authorisation-application-modernas-mrna-1273-covid-19-vaccine
Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna’s Vaccine Against COVID-19 in the United States (Hinzugefügt: 18.12.2020 um 10:20 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-advisory-committee-vote-supporting/
Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Announcement (Hinzugefügt: 17.12.2020 um 18:24 Uhr)
https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-17-2020-meeting-announcement
SARS-CoV-2: FDA bescheinigt Impfstoff von Moderna gute Wirkung und hohe Sicherheit (Hinzugefügt: 16.12.2020 um 07:54 Uhr)
https://www.aerzteblatt.de/nachrichten/119425/SARS-CoV-2-FDA-bescheinigt-Impfstoff-von-Moderna-gute-Wirkung-und-hohe-Sicherheit
FDA Briefing Document Moderna COVID-19 Vaccine (Hinzugefügt: 15.12.2020 um 18:59 Uhr)
https://www.fda.gov/media/144434/download
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults List of authors. (Hinzugefügt: 12.12.2020 um 08:59 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2028436
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (Hinzugefügt: 12.12.2020 um 08:59 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2032195
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (Hinzugefügt: 12.12.2020 um 08:59 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2022483
trial protocol (Hinzugefügt: 12.12.2020 um 08:59 Uhr)
https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/nejmoa2022483_protocol.pdf
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Adolescents (Hinzugefügt: 11.12.2020 um 08:07 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-covid/

Mehr zum Thema "Impfungen Wuhan-type Originalvirus: in D in Vergangenheit verfügbare Impfstoffe gegen Originalvirus"

Nuvaxovid (Novavax) 12. Dezember 2020 09:54 Valneva 13. Januar 2021 09:09 Sanofi 14. November 2022 14:15 Johnson & Johnson/ Janssen 18. Dezember 2020 22:46 Vaxzevria/ Covishield (Astra Zeneca/ Oxford) - Original AZD1222 10. Dezember 2020 10:51 Spikevax (Moderna) - Original 11. Dezember 2020 09:07 Comirnaty (BioNTech/ Pfizer) - Original 10. Dezember 2020 10:42

Weitere Themen

SARS-CoV-2 Pandemie Virus SARS-Cov-2 Masken/ masks Luftreiniger Risikoreduktion Impfungen Wuhan-type Originalvirus: in D in Vergangenheit verfügbare Impfstoffe gegen Originalvirus Impfungen BA.1: in D verfügbar gewesener angepasste Impfstoffe gegen Omicron BA.1 Impfung BA.2: Impfstoff gg BA.2 Impfung BA.4/5: in D in 2022/23 verfügbar gewesene Impfstoffe gegen BA.4/5 Impfung XBB: in D in 2023/24 verfügbar gewesene XBB- Booster Impfung JN.1/ KP.2: Herbst 2024 in D verfügbare Impfstoffe PrEP Tests Erkrankung - Symptome Covid-19 Risikopatienten Frühtherapie Behandlung monoklonale Antikörper 14y evtl. wirksame Behandlung 14z nicht empfohlene Behandlung 15 Long- Covid/ Post- Covid 16 Rechtliches/ legal information 17 Meine persönliche Vorgehensweise/ My personal approach 18 NICHT SARS-CoV-2 Übertragung Übertragungssituationen 2c Reisen/ travelling 3 NPIs 7y Immunität nach Infektion/ immunity after infection 0 alt Corona- Pandemie 10 Was tun wenn infiziert?/ To do when tested positive? 7a allg. zu Impfungen/ vaccinations

« Zurück zur Übersicht